Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Mechanism SSTR2 antagonists(Somatostatin receptor 2 antagonists), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuroendocrine Tumors | Phase 1 | AT | 23 Dec 2022 | |
Neuroendocrine Tumors | Phase 1 | AT | 23 Dec 2022 | |
Neuroendocrine Tumors | Phase 1 | AT | 23 Dec 2022 | |
Neuroendocrine Tumors | Phase 1 | PL | 23 Dec 2022 | |
Neuroendocrine Tumors | Phase 1 | PL | 23 Dec 2022 | |
Neuroendocrine Tumors | Phase 1 | PL | 23 Dec 2022 | |
Neuroendocrine Tumors | Phase 1 | SI | 23 Dec 2022 | |
Neuroendocrine Tumors | Phase 1 | SI | 23 Dec 2022 | |
Neuroendocrine Tumors | Phase 1 | SI | 23 Dec 2022 |